SIGA
$5.02
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus...
Recent News
Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look.
New York City officials have confirmed the first case of a more severe strain case of mpox. Mpox, formerly known as monkeypox, is a viral infection characterized by a flu-like fever and rash that can last weeks. It’s caused by a virus in the same family as smallpox, though it’s less contagious and less dangerous.
SIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract Wins
SIGA Technologies, Inc. recently reported its fourth quarter and full-year 2025 results, with full-year revenue of US$94.57 million and net income of US$23.28 million, but a sharp year-on-year drop in quarterly revenue to US$3.8 million and a quarterly net loss of US$5.4 million. Alongside these results, SIGA highlighted a strong cash position of about US$155 million with no debt, fresh BARDA funding of US$27 million, and a new multi-year international oral TPOXX order of US$13 million that...
A Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract Progress
SIGA Technologies (SIGA) is back in focus after its 2025 earnings release, which showed lower annual revenue and net income, alongside ongoing contracts for TPOXX, pediatric development funding, and active regulatory reviews in Europe. See our latest analysis for SIGA Technologies. That weaker 2025 earnings print has come alongside fading momentum in the share price. SIGA Technologies has posted a 1 month share price return of 22.53% and a year to date share price return decline of 16.11%,...
SIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy Revenue
SIGA Technologies (NasdaqGM:SIGA) has secured new multi-year international contracts for its antiviral TPOXX. The company recently received a $13 million procurement order from a country in the Asia Pacific region. SIGA has also obtained $27 million in U.S. government funding for pediatric formulation work and IV technology transfer for TPOXX. The company is engaging with regulators in Europe and the U.S. on TPOXX related matters. NasdaqGM:SIGA is drawing fresh attention as it adds new...
SIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...
SIGA Technologies Inc (SIGA) reports robust revenues and maintains a solid cash position, while exploring strategic opportunities for future growth.